Clinical correlation of the binding potential with 123I-FP-CIT in de novo idiopathic Parkinson's disease patients

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 12, 2008, Pages 2220-2226

  Berti, Valentina ^a   Pupi, Alberto ^a   Ramat, Silvia ^a   Vanzi, Eleonora ^a   De Cristofaro, Maria Teresa ^a   Pellicanò, Giannantonio ^a   Mungai, Francesco ^a   Marini, Paolo ^a   Sorbi, Sandro ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

123I FP CIT; Binding potential; Biomarker; Parkinson's disease; Severity

Indexed keywords

N OMEGA FLUOROPROPYL 2BETA CARBOMETHOXY 3BETA 4 IODOPHENYLNORTROPANE I 123; NORTROPANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG PROTEIN BINDING; FEMALE; HUMAN; IMAGE RECONSTRUCTION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PUTAMEN; QUANTITATIVE DIAGNOSIS; REGRESSION ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; AGED, 80 AND OVER; CORPUS STRIATUM; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 58149289489     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0872-4     Document Type: Article

References (36)

1. JM Fearnley AJ Lees 1991 Ageing and Parkinson's disease: substantia nigra regional selectivity Brain 114 2283 2301
2. MJ Kaufman BK Madras 1991 Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's disease striatum Synapse 9 43 49
3. JP Seibyl 2003 Imaging studies in movement disorders Semin Nucl Med 33 105 113
4. JP Seibyl K Marek K Sheff S Zoghbi RM Baldwin DS Charney 1998 Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurements of dopamine transporters in healthy subjects and Parkinson's patients J Nucl Med 39 1500 1508
5. V Marshall D Grosset 2003 Role of dopamine transporter imaging in routine clinical practice Mov Disord 18 1415 1423
6. HTS Benamer J Patterson DG Grosset J Booij K de Bruin E van Royen 2000 Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group Mov Disord 15 503 510
7. M Plotkin H Amthauer S Klaffke A Kuhn L Ludemann G Arnold 2005 Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients J Neural Transm 112 5 677 692
8. J Booij JB Habraken P Bergmans G Tissingh A Winogrodzka EC Wolters 1998 Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease J Nucl Med 39 11 1879 1884
9. 123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease Eur J Nucl Med 24 68 71
10. G Tissingh J Booij P Bergmans A Winogrodzka A Janssen E Van Royen 1998 Iodine-123-N-ω-fluoropropyl-2-β-carbomethoxy-3β-(4-iodophenyl) tropane SPECT in healthy controls and early stage, drug-naive Parkinson's disease J Nucl Med 39 1143 1148
11. RB Innis VJ Cunningham J Delforge M Fujita A Gjedde RN Gunn 2007 Consensus nomenclature for in vivo imaging of reversibly binding radioligands J Cereb Blood Flow Metab 27 9 1533 1539
12. 123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism Eur J Nucl Med 28 266 272
13. IU Isaias R Benti R Cilia M Canesi G Marotta P Gerundini 2007 [123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset NeuroReport 18 1499 1502
14. W Koch PE Randau K Tatsch 2005 Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies J Nucl Med 46 7 1109 1118
15. AW Michell SJG Lewis T Foltynie RA Barker 2004 Biomarkers and Parkinson's disease Brain 127 1693 1705
16. J Spiegel G Hellwig S Samnick W Jost MO Mollers K Fassbender 2007 Striatal FP-CIT uptake differs in subtypes of early Parkinson's disease J Neural Transm 114 3 331 335
17. SA Eshuis RP Maguire KL Leenders S Jonkman PL Jager 2006 Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease Eur J Nucl Med Mol Imaging 33 200 209
18. HTS Benamer J Patterson DJ Wyper DM Hadley GJA Macphee DG Grosset 2000 Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake Mov Disord 15 692 698
19. M Soret PM Koulibaly J Darcourt S Hapdey I Buvat 2003 Quantitative accuracy of dopaminergic neurotransmission imaging with 123I SPECT J Nucl Med 44 7 1184 1193
20. AR Formiconi A Passeri P Calvini 1999 Theoretical determination of the collimator geometrical transfer function for the reconstruction of SPECT data IEEE Trans Nucl Sci 46 4 1075 1080
21. OG Rousset Y Ma AC Evans 1998 Correction for partial volume effects in PET: principle and validation J Nucl Med 39 5 904 911
22. AR Formiconi 1993 Least squares algorithm for region of interest evaluation in emission tomography IEEE Trans Med Imag 2 1 90 100
23. E Vanzi MT De Cristofaro S Ramat B Sotgia M Mascalchi AR Formiconi 2007 A direct ROI quantification method for inherent PVE correction: accuracy assessment in striatal SPECT measurements Eur J Nucl Med Mol Imaging 34 9 1480 1489
24. A Hughes Y Ben-Shlomo SE Daniel AJ Lees 1992 What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinico-pathological study Neurology 42 1142 1146
25. MM Hoehn MD Yahr 1967 Parkinsonism: onset, progression and mortality Neurology 17 427 442
26. Fahn S, Elton RL, and members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent development in Parkinson's disease. Florham Park, HJ: Macmillan Healthcare Information; 1987. p. 153-64.
27. HM Hudson RS Larkin 1994 Accelerated image reconstruction using ordered subsets of projection data IEEE Transm Med Imaging 13 4 601
28. L Chang 1987 A method for attenuation correction in computed tomography IEEE Trans Nucl Sci 25 638 664
29. National Institutes of Health. Medical image processing, analysis and visualization. www.mipav.cit.nih.gov (as achieved in January 24th, 2008)
30. McAuliffe MJ, Lalonde D, McGarry D, Gandler W, Csaky K, Trus BL. Medical image processing, analysis and visualization in clinical research. In: CBMS'01: 2001 Proceedings of the IEEE Computer-based Medical Systems, Bethesda, MD, p. 381.
31. M Laruelle E Wallace JP Seibyl RM Baldwin Y Zea-Ponce SS Zoghbi 1994 Graphical, kinetic and equilibrium analyses of in vivo [123I]β-CIT binding to dopamine transporters in healthy human subjects J Cereb Blood Flow Metab 14 982 994
32. W Pirker 2003 Correlation of dopamine transporter imaging and parkinsonian motor handicap: how close is it? Mov Disord 18 Suppl 7 S43 S51
33. JP Seibyl KL Marek D Quinlan K Sheff S Zoghbi Y Zea-Ponce 1995 Decreased single photon emission computed tomographic [123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease Ann Neurol 38 589 598
34. T Brucke S Asenbaum W Pirker S Djamshidian S Wenger C Wober 1997 Measurement of the dopaminergic degeneration in Parkinson's disease with [123I]β-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy J Neural Transm 50 Suppl 9 24
35. S Asenbaum T Brucke W Pirker I Podreka P Angelberger S Wenger 1997 Imaging of dopamine transporters with iodine-123-β-CIT and SPECT in Parkinson's disease J Nucl Med 38 1 6
36. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease 2003 The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations Mov Disord 18 738 750